Eton Pharmaceuticals rises after Q2 beat and FY26 revenue guidance
Eton Pharmaceuticals said second-quarter earnings were 43 cents a share versus the 10-cent consensus and sales were $37.568 million versus $27.119 million, while FY26 revenue guidance came in above estimates.